1) Concerns exist that drospirenone-containing combined oral contraceptives (OCs), the norelgestromin patch, and the etonogestrel
vaginal ring may increase the risk of VTE, compared with second-generation OCs, although results from studies evaluating the thromboembolic risk of these products are conflicting.
He mentioned a recent study by Tocce and colleagues, in which new mothers were offered a choice between insertion of an etonogestrel
implant before hospital discharge or initiation of any contraceptive at the postpartum follow-up visit.
He and his associates conducted two crossover studies to determine whether treatment with amoxicillin and doxycycline affects the pharmacokinetics of ethinyl estradiol and etonogestrel
released from the NuvaRing.
It is designed to release 120 [mu]g etonogestrel
and 15 [mu]g ethinyl estradiol daily, a dose that is actually lower than the 150 [mu]g desogestrel and 20 [mu]g ethinyl estradiol provided by the lowest-dose daily combination oral regimen.
There are three LARC methods available in the United States: 1) the copper T380A intrauterine device (IUD; Paragard), 2) the levonorgestrel-releasing intrauterine system (Mirena), and 3) the single-rod etonogestrel
implant (Implanon, Explanon).
She asks if she can have an etonogestrel
implant placed prior to her discharge.
1) For women using an IUD or etonogestrel
implant, the contraceptive failure rate was 0.
In a pilot study of an etonogestrel
releasing implant (Implanon), 41 women who had pelvic pain and endometriosis were randomized to receive the implant or DMPA, 150 mg IM, every 3 months for 1 year.
The maximum concentration of etonogestrel
is reached 200 hours after insertion and the maximum concentration of ethinyl estradiol is reached 59 hours after insertion, compared with 1.
It is designed to release 120 [micro]g etonogestrel
and 15 [micro]g ethinyl estradiol daily, a dose that is actually lower than the 150 [micro]g desogestrel and 20 [micro]g ethinyl estradiol provided by the lowest-dose daily combination oral regimen.
If the patient does not desire a combination OC or has other contraindications to estrogen, she may benefit from a progestin--only contraceptive that suppresses ovulation, such as DMPA or the etonogestrel
for the development of an injectable etonogestrel
contraceptive with 6- and 12-month durations.